abstract: BACKGROUND: Tissue Doppler imaging (TDI) is a noninvasive echocardiographic method for the diagnosis of @entity67 in @entity1 with varying degrees of @entity472 ( @entity472 ). Little is known however, on the utility of TDI in the serial assessment of @entity854 in @entity472 . OBJECTIVE: The aim of the current proposal was to examine whether treatment with @entity8671 was successful in improving @entity854 in @entity1 enrolled in the Aortic Stenosis Progression Observation Measuring Effects of @entity8671 (ASTRONOMER) study. METHODS: Conventional Doppler indices including peak early (E) and late (A) transmitral velocities, and E/A ratio were measured from spectral Doppler. Tissue Doppler measurements including early (E') and late (A') velocities of the lateral annulus were determined, and E/E' was calculated. RESULTS: The study population included 168 @entity1 (56    13 years), whose @entity472 severity was categorized based on peak velocity at baseline (Group I: 2.5-3.0 m/s; Group II: 3.1-3.5 m/s; Group III: 3.6-4.0 m/s). Baseline and follow-up hemodynamics, LV dimensions and diastolic functional parameters were evaluated in all three groups. There was increased @entity67 from baseline to follow-up in each of the placebo and @entity8671 groups. In @entity1 with increasing severity of @entity472 in Groups I and II, the lateral E' was lower and the E/E' (as an estimate of increased left ventricular end-diastolic pressure) was higher at baseline (p < 0.05). However, treatment with @entity8671 did not affect the progression of @entity67 from baseline to 3.5 year follow-up between @entity1 in any of the three predefined groups. CONCLUSION: In @entity1 with mild to moderate asymptomatic @entity472 , @entity8671 did not attenuate the progression of @entity67 .

title: Evaluating the effectiveness of @entity8671 in preventing the progression of @entity67 in @entity472 : A substudy of the XXXX progression observation measuring effects of @entity8671 (ASTRONOMER) study.

answer: @entity472 :: (MESH:D001024,Disease) :: ['aortic stenosis']


abstract: BACKGROUND: Tissue Doppler imaging (TDI) is a noninvasive echocardiographic method for the diagnosis of @entity67 in @entity1 with varying degrees of @entity472 ( @entity472 ). Little is known however, on the utility of TDI in the serial assessment of @entity854 in @entity472 . OBJECTIVE: The aim of the current proposal was to examine whether treatment with @entity8671 was successful in improving @entity854 in @entity1 enrolled in the Aortic Stenosis Progression Observation Measuring Effects of @entity8671 (ASTRONOMER) study. METHODS: Conventional Doppler indices including peak early (E) and late (A) transmitral velocities, and E/A ratio were measured from spectral Doppler. Tissue Doppler measurements including early (E') and late (A') velocities of the lateral annulus were determined, and E/E' was calculated. RESULTS: The study population included 168 @entity1 (56    13 years), whose @entity472 severity was categorized based on peak velocity at baseline (Group I: 2.5-3.0 m/s; Group II: 3.1-3.5 m/s; Group III: 3.6-4.0 m/s). Baseline and follow-up hemodynamics, LV dimensions and diastolic functional parameters were evaluated in all three groups. There was increased @entity67 from baseline to follow-up in each of the placebo and @entity8671 groups. In @entity1 with increasing severity of @entity472 in Groups I and II, the lateral E' was lower and the E/E' (as an estimate of increased left ventricular end-diastolic pressure) was higher at baseline (p < 0.05). However, treatment with @entity8671 did not affect the progression of @entity67 from baseline to 3.5 year follow-up between @entity1 in any of the three predefined groups. CONCLUSION: In @entity1 with mild to moderate asymptomatic @entity472 , @entity8671 did not attenuate the progression of @entity67 .

title: Evaluating the effectiveness of @entity8671 in preventing the progression of XXXX in @entity472 : A substudy of the @entity472 progression observation measuring effects of @entity8671 (ASTRONOMER) study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8671 :: ('MESH:C422923', 'Chemical') :: ['rosuvastatin', 'Rosuvastatin']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['AS', 'aortic stenosis']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['diastolic abnormalities']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['diastolic dysfunction']

answer: @entity67 :: (MESH:D018754,Disease) :: ['diastolic dysfunction']


abstract: BACKGROUND: Tissue Doppler imaging (TDI) is a noninvasive echocardiographic method for the diagnosis of @entity67 in @entity1 with varying degrees of @entity472 ( @entity472 ). Little is known however, on the utility of TDI in the serial assessment of @entity854 in @entity472 . OBJECTIVE: The aim of the current proposal was to examine whether treatment with @entity8671 was successful in improving @entity854 in @entity1 enrolled in the Aortic Stenosis Progression Observation Measuring Effects of @entity8671 (ASTRONOMER) study. METHODS: Conventional Doppler indices including peak early (E) and late (A) transmitral velocities, and E/A ratio were measured from spectral Doppler. Tissue Doppler measurements including early (E') and late (A') velocities of the lateral annulus were determined, and E/E' was calculated. RESULTS: The study population included 168 @entity1 (56    13 years), whose @entity472 severity was categorized based on peak velocity at baseline (Group I: 2.5-3.0 m/s; Group II: 3.1-3.5 m/s; Group III: 3.6-4.0 m/s). Baseline and follow-up hemodynamics, LV dimensions and diastolic functional parameters were evaluated in all three groups. There was increased @entity67 from baseline to follow-up in each of the placebo and @entity8671 groups. In @entity1 with increasing severity of @entity472 in Groups I and II, the lateral E' was lower and the E/E' (as an estimate of increased left ventricular end-diastolic pressure) was higher at baseline (p < 0.05). However, treatment with @entity8671 did not affect the progression of @entity67 from baseline to 3.5 year follow-up between @entity1 in any of the three predefined groups. CONCLUSION: In @entity1 with mild to moderate asymptomatic @entity472 , @entity8671 did not attenuate the progression of @entity67 .

title: Evaluating the effectiveness of XXXX in preventing the progression of @entity67 in @entity472 : A substudy of the @entity472 progression observation measuring effects of @entity8671 (ASTRONOMER) study.

answer: @entity8671 :: (MESH:C422923,Chemical) :: ['rosuvastatin']


abstract: BACKGROUND: Tissue Doppler imaging (TDI) is a noninvasive echocardiographic method for the diagnosis of @entity67 in @entity1 with varying degrees of @entity472 ( @entity472 ). Little is known however, on the utility of TDI in the serial assessment of @entity854 in @entity472 . OBJECTIVE: The aim of the current proposal was to examine whether treatment with @entity8671 was successful in improving @entity854 in @entity1 enrolled in the Aortic Stenosis Progression Observation Measuring Effects of @entity8671 (ASTRONOMER) study. METHODS: Conventional Doppler indices including peak early (E) and late (A) transmitral velocities, and E/A ratio were measured from spectral Doppler. Tissue Doppler measurements including early (E') and late (A') velocities of the lateral annulus were determined, and E/E' was calculated. RESULTS: The study population included 168 @entity1 (56    13 years), whose @entity472 severity was categorized based on peak velocity at baseline (Group I: 2.5-3.0 m/s; Group II: 3.1-3.5 m/s; Group III: 3.6-4.0 m/s). Baseline and follow-up hemodynamics, LV dimensions and diastolic functional parameters were evaluated in all three groups. There was increased @entity67 from baseline to follow-up in each of the placebo and @entity8671 groups. In @entity1 with increasing severity of @entity472 in Groups I and II, the lateral E' was lower and the E/E' (as an estimate of increased left ventricular end-diastolic pressure) was higher at baseline (p < 0.05). However, treatment with @entity8671 did not affect the progression of @entity67 from baseline to 3.5 year follow-up between @entity1 in any of the three predefined groups. CONCLUSION: In @entity1 with mild to moderate asymptomatic @entity472 , @entity8671 did not attenuate the progression of @entity67 .

title: Evaluating the effectiveness of @entity8671 in preventing the progression of @entity67 in @entity472 : A substudy of the @entity472 progression observation measuring effects of XXXX (ASTRONOMER) study.

answer: @entity8671 :: (MESH:C422923,Chemical) :: ['rosuvastatin']


abstract: AIM: To assess the clinical time (diagnosis and treatment times) to manage traumatic @entity8495 (TDIs) in @entity1 attending paediatric dental clinics in Nigeria. STUDY DESIGN: Cross sectional observational pilot study on @entity1 presenting at four government hospitals in South West Nigeria over a 3-month period. METHODS: @entity8495 was classified using the method recommended by Andreasen et al. [2003]. A standardized protocol was followed and the details of the diagnosis time, treatment time and total clinical time for management of different @entity130 to the primary and permanent dentition were recorded and calculated on a data collection form. RESULTS: There were 73 @entity8495 in 39 @entity1 . For the primary dentition, complicated crown @entity174 had the highest average total treatment time namely 76.0  48.1 minutes as well as the highest average number of visits (2.6 visits). More time was spent manageing the same level of injury in the permanent dentition than in the primary dentition. For the permanent dentition, extrusive @entity130 had the highest average total treatment time (103.3  11.5 minutes). CONCLUSION: The clinical time for management of @entity8495 in @entity1 was relatively high and varied by @entity130 .

title: Assessment of time taken to treat XXXX in Nigerian @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity8495 :: ('MESH:D018677', 'Disease') :: ['Dental injury', 'dental injuries']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['traumatic injuries', 'type of injury', 'luxation injury']

answer: @entity130 :: (MESH:D014947,Disease) :: ['dental trauma']


abstract: AIM: To assess the clinical time (diagnosis and treatment times) to manage traumatic @entity8495 (TDIs) in @entity1 attending paediatric dental clinics in Nigeria. STUDY DESIGN: Cross sectional observational pilot study on @entity1 presenting at four government hospitals in South West Nigeria over a 3-month period. METHODS: @entity8495 was classified using the method recommended by Andreasen et al. [2003]. A standardized protocol was followed and the details of the diagnosis time, treatment time and total clinical time for management of different @entity130 to the primary and permanent dentition were recorded and calculated on a data collection form. RESULTS: There were 73 @entity8495 in 39 @entity1 . For the primary dentition, complicated crown @entity174 had the highest average total treatment time namely 76.0  48.1 minutes as well as the highest average number of visits (2.6 visits). More time was spent manageing the same level of injury in the permanent dentition than in the primary dentition. For the permanent dentition, extrusive @entity130 had the highest average total treatment time (103.3  11.5 minutes). CONCLUSION: The clinical time for management of @entity8495 in @entity1 was relatively high and varied by @entity130 .

title: Assessment of time taken to treat @entity130 in Nigerian XXXX .

answer: @entity1 :: (9606,Species) :: ['children']


abstract: AIM: The aim of the present action research study was to investigate the healthcare providers' experiences with introducing Marte Meo Counselling (MMC) in a @entity303 -specific care unit. BACKGROUND: Research on the use of MMC shows that healthcare providers saw the @entity1 ' resources and needs more clearly and achieved increased awareness of their own skills. DESIGN AND METHOD: An action-oriented research including a three-phase strategy was applied: the mapping phase, the intervention phase and the evaluation phase. During the 5-month mapping phase, two researchers conducted @entity1 observation of a total of 50 hours. The intervention phase consisted of lectures, clinical supervision in MMC and seven reflection groups and lasted 12 months. In the six-month evaluation phase, @entity1 observation of a total of 48 hours was conducted. Four focus group interviews took place during the whole study period of 2 years. RESULTS: The staff went through a process of change described by the following themes: from challenging behaviour to challenging interaction; from generalised skills to contextualised relational care; and from personal challenges to a professional community. CONCLUSIONS: As a result of MMC, the healthcare providers realised the value of taking into account the @entity1 ' context in @entity303 care and of being active @entity1 in the @entity1 ' world. The focus changed from regarding challenging behaviour as symptoms of a disorder to being a challenge to interaction. IMPLICATIONS FOR PRACTICE: Marte Meo Counselling should be combined with continuous reflection to improve healthcare providers' interaction with @entity1 who live with @entity303 . The reflection groups gave the caregivers an opportunity for discussions that would otherwise be impossible in their busy everyday life.

title: 'On one's own strength' Healthcare providers' experience with introducing Marte Meo Counselling in XXXX care.

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'participant', 'people']

answer: @entity303 :: (MESH:D003704,Disease) :: ['dementia']


abstract: BACKGROUND: As life expectancy increases, more elderly @entity1 fit into the criteria for bariatric procedures. The aim of our study is to evaluate and compare the safety and efficacy of @entity356 ( @entity356 ), laparoscopic sleeve gastrectomy (LSG), and laparoscopic adjustable gastric banding (LAGB) in @entity1 older than 60. MATERIAL AND METHODS: Between January 2005 and December 2013, 68 LAGB, 73 LSG, and 212 @entity356 @entity1 were 60  years or older at the time of primary procedure. A retrospective review was performed in these @entity1 . RESULTS: Mean age and body mass index (BMI) was 62.7        2.2, 64.1        2.9, and 62.6        2.3  years and 42.7        5.6, 44.0        7.0, and 45.2        6.7  kg/m(2) for LAGB, LSG, and @entity356 at the time of procedure, respectively. Seven (10.3  %) @entity1 from the LAGB, 3 (4.1  %) from the LSG, and 29 (13.8  %) from the @entity356 group required readmissions. Reoperation rate was 10.3, 1.4, and 9.5  % in LAGB, LSG, and @entity356 , respectively. The difference in reoperation rates was statistically significant (p   <   0.03) while that in readmission rates was not (p   >   0.58). Procedure-related mortality rate was 1.4  % in the @entity356 group, while no mortality was observed in LSG and LAGB groups. At 6, 12, and 18  months postoperatively, mean percentage of excess @entity353 were highest in the @entity356 group, followed by LSG and LAGB group (p   <   0.01). Mean number of comorbidities at the last follow-up significantly decreased in LSG and @entity356 @entity1 . CONCLUSIONS: LSG showed the lowest readmission and reoperation rate, and @entity356 @entity1 had the highest mortality rate. Weight loss and comorbidity resolution were effectively achieved in @entity356 and LSG @entity1 .

title: Morbidity Rates and Weight Loss After Roux-en-Y Gastric Bypass, Sleeve Gastrectomy, and Adjustable Gastric Banding in XXXX Older Than 60  Years old: Which Procedure to Choose?

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['Roux-en-Y gastric bypass', 'RYGB']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: Health care practitioners support or hinder an individual's attempts to self-manage health behavior. Practitioners must understand an individual's health needs and goals to effectively partner for behavior change. @entity14062 ( @entity14062 ) promote efforts toward positive health behavior change. Practitioners need training to provide effective @entity14062 , beginning with their formal education. The purpose of this educational practice project was to integrate an evidence-based intervention ( @entity14062 using action plans) into a nursing curriculum. Three sequential steps included (1) providing foundational @entity14062 education, (2) @entity14062 application with students' personal action plans, and (3) implementing @entity14062 with @entity497 individuals with @entity6 . Students (n = 130) partnered with @entity1 (n = 85), developing short- (n = 240) and long-term (n = 99) action plans during home visits. The average baseline @entity6 Empowerment Scale score measuring @entity1 's perceived psychosocial @entity6 management self-efficacy was 4.3 (1-5 scale, SD = 0.51, n = 83). Most common short-term actions related to physical activity (n = 100, 42%) and healthy eating (n = 61, 25%). Average @entity1 confidence level was 7.7 (SD = 1.9, 0-10 scale). Short-term goal evaluation (n = 209) revealed 66% (n = 137) were met more than 50% of the time. Both @entity1 (99%) and students (99%) expressed satisfaction with home visit and action plan experiences. This teaching-learning experience is replicable and applicable to any professional health care student.

title: Partnering With XXXX Individuals With @entity6 for Health Behavior Change Using Action Plans: An Innovation in Health Professionals Education and Practice.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'participant']

entities_list: @entity497 :: ('MESH:D003147', 'Disease') :: ['community-dwelling']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

entities_list: @entity14062 :: ('MESH:D012652', 'Disease') :: ['Self-management support', 'SMS']

answer: @entity497 :: (MESH:D003147,Disease) :: ['Community-Dwelling']


abstract: Health care practitioners support or hinder an individual's attempts to self-manage health behavior. Practitioners must understand an individual's health needs and goals to effectively partner for behavior change. @entity14062 ( @entity14062 ) promote efforts toward positive health behavior change. Practitioners need training to provide effective @entity14062 , beginning with their formal education. The purpose of this educational practice project was to integrate an evidence-based intervention ( @entity14062 using action plans) into a nursing curriculum. Three sequential steps included (1) providing foundational @entity14062 education, (2) @entity14062 application with students' personal action plans, and (3) implementing @entity14062 with @entity497 individuals with @entity6 . Students (n = 130) partnered with @entity1 (n = 85), developing short- (n = 240) and long-term (n = 99) action plans during home visits. The average baseline @entity6 Empowerment Scale score measuring @entity1 's perceived psychosocial @entity6 management self-efficacy was 4.3 (1-5 scale, SD = 0.51, n = 83). Most common short-term actions related to physical activity (n = 100, 42%) and healthy eating (n = 61, 25%). Average @entity1 confidence level was 7.7 (SD = 1.9, 0-10 scale). Short-term goal evaluation (n = 209) revealed 66% (n = 137) were met more than 50% of the time. Both @entity1 (99%) and students (99%) expressed satisfaction with home visit and action plan experiences. This teaching-learning experience is replicable and applicable to any professional health care student.

title: Partnering With @entity497 Individuals With XXXX for Health Behavior Change Using Action Plans: An Innovation in Health Professionals Education and Practice.

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetes']


abstract: Insulin might play a role in the @entity101 occurring in @entity6 . In addition, insulin has recently been shown to potentiate @entity1063 (NE) induced vascular tone. We used ring segments of the @entity95 facial artery mounted in a myograph to test the hypothesis that potentiation of NE-induced tone by insulin may be related to activation of @entity7131 ( @entity7131 ) and @entity669 kinase (TK). NE-induced contractions in the presence of @entity8446 were 200% (NE 0.1 and 0.3 microM), 252% (NE 1 microM), and 129% (NE 3 microM) of control. @entity8446 had no effect on NE (10 and 100 microM) induced contractions. The potentiation by insulin of NE-induced tone was not altered by endothelium removal and could be mimicked by @entity1359 ( @entity4515 , 0.1 microM). @entity112 -induced contractions were not altered by @entity8446 . Insulin potentiation of NE-induced tone was suppressed by pretreatment of the @entity95 facial artery with the @entity7131 inhibitor @entity11616 (0.1 microM) or the TK inhibitor @entity670 (10 microM). 45Ca2+ influx due to NE (3 microM) did not change in the presence of @entity8446 or @entity4515 (0.1 microM) despite a higher contractile response, so that wall force per unit of 45Ca2+ influx was increased by @entity8446 and @entity4515 (0.1 microM). Calphostin C (0.1 microM) and @entity670 (10 microM) both prevented the increase in wall force per unit of 45Ca2+ influx due to @entity8446 . Our study shows that insulin potentiates NE-induced tone through a TK- and @entity7131 -dependent mechanism.

title: Insulin potentiates XXXX -induced vascular tone by activation of @entity7131 and @entity669 kinase.

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['insulin-resistant diabetes']

entities_list: @entity670 :: ('MESH:D019833', 'Chemical') :: ['genistein']

entities_list: @entity1359 :: ('CHEBI:37537', 'Chemical') :: ['phorbol-12-myristate-13-acetate']

entities_list: @entity7131 :: ('MESH:D020151', 'Disease') :: ['protein kinase C', 'PKC']

entities_list: @entity112 :: ('MESH:D006632', 'Chemical') :: ['Histamine']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

entities_list: @entity11616 :: ('MESH:C058819', 'Chemical') :: ['calphostin C']

answer: @entity1063 :: (MESH:D009638,Chemical) :: ['norepinephrine']


abstract: Insulin might play a role in the @entity101 occurring in @entity6 . In addition, insulin has recently been shown to potentiate @entity1063 (NE) induced vascular tone. We used ring segments of the @entity95 facial artery mounted in a myograph to test the hypothesis that potentiation of NE-induced tone by insulin may be related to activation of @entity7131 ( @entity7131 ) and @entity669 kinase (TK). NE-induced contractions in the presence of @entity8446 were 200% (NE 0.1 and 0.3 microM), 252% (NE 1 microM), and 129% (NE 3 microM) of control. @entity8446 had no effect on NE (10 and 100 microM) induced contractions. The potentiation by insulin of NE-induced tone was not altered by endothelium removal and could be mimicked by @entity1359 ( @entity4515 , 0.1 microM). @entity112 -induced contractions were not altered by @entity8446 . Insulin potentiation of NE-induced tone was suppressed by pretreatment of the @entity95 facial artery with the @entity7131 inhibitor @entity11616 (0.1 microM) or the TK inhibitor @entity670 (10 microM). 45Ca2+ influx due to NE (3 microM) did not change in the presence of @entity8446 or @entity4515 (0.1 microM) despite a higher contractile response, so that wall force per unit of 45Ca2+ influx was increased by @entity8446 and @entity4515 (0.1 microM). Calphostin C (0.1 microM) and @entity670 (10 microM) both prevented the increase in wall force per unit of 45Ca2+ influx due to @entity8446 . Our study shows that insulin potentiates NE-induced tone through a TK- and @entity7131 -dependent mechanism.

title: Insulin potentiates @entity1063 -induced vascular tone by activation of @entity7131 and XXXX kinase.

answer: @entity669 :: (CHEBI:18186,Chemical) :: ['tyrosine']


abstract: Insulin might play a role in the @entity101 occurring in @entity6 . In addition, insulin has recently been shown to potentiate @entity1063 (NE) induced vascular tone. We used ring segments of the @entity95 facial artery mounted in a myograph to test the hypothesis that potentiation of NE-induced tone by insulin may be related to activation of @entity7131 ( @entity7131 ) and @entity669 kinase (TK). NE-induced contractions in the presence of @entity8446 were 200% (NE 0.1 and 0.3 microM), 252% (NE 1 microM), and 129% (NE 3 microM) of control. @entity8446 had no effect on NE (10 and 100 microM) induced contractions. The potentiation by insulin of NE-induced tone was not altered by endothelium removal and could be mimicked by @entity1359 ( @entity4515 , 0.1 microM). @entity112 -induced contractions were not altered by @entity8446 . Insulin potentiation of NE-induced tone was suppressed by pretreatment of the @entity95 facial artery with the @entity7131 inhibitor @entity11616 (0.1 microM) or the TK inhibitor @entity670 (10 microM). 45Ca2+ influx due to NE (3 microM) did not change in the presence of @entity8446 or @entity4515 (0.1 microM) despite a higher contractile response, so that wall force per unit of 45Ca2+ influx was increased by @entity8446 and @entity4515 (0.1 microM). Calphostin C (0.1 microM) and @entity670 (10 microM) both prevented the increase in wall force per unit of 45Ca2+ influx due to @entity8446 . Our study shows that insulin potentiates NE-induced tone through a TK- and @entity7131 -dependent mechanism.

title: Insulin potentiates @entity1063 -induced vascular tone by activation of XXXX and @entity669 kinase.

answer: @entity7131 :: (MESH:D020151,Disease) :: ['protein kinase C']


abstract: STUDY OBJECTIVE: To report the usual postoperative course and complications after pull-through vaginoplasty for isolated distal vaginal @entity1146 . DESIGN, SETTING, AND @entity1 : Retrospective chart review at Texas @entity1 's Hospital of all @entity1 who were diagnosed with isolated distal vaginal @entity1146 and underwent pull-through vaginoplasty during the study time frame. INTERVENTIONS: None. MAIN OUTCOME MEASURES: @entity260 such as @entity850 or @entity281 and postoperative vaginal diameter. RESULTS: Sixteen @entity1 were identified and charts were reviewed. @entity1 were initially evaluated by pelvic magnetic resonance imaging and found to have distended hematometrocolpos with distal vaginal @entity1146 . All @entity1 underwent pull-through vaginoplasty with similar operative techniques. The average distance from the perineum to the level of the obstruction was 1.84    1.2 cm. Two @entity1 , both with obstructions at greater than 3 cm, experienced @entity850 formation postoperatively. Four @entity1 (25%) experienced postoperative @entity365 . One @entity1 (6.25%) experienced a @entity293 . Two groups (3 cm or less versus greater than 3 cm) were compared, and the presence of @entity850 was statistically different based on mean centimeters from perineum prior to pull-through vaginoplasty (P = .038). CONCLUSIONS: Distal vaginal @entity1146 is managed with pull-through vaginoplasty. Atresias that extend greater than 3 cm from the perineum are at increased risk for @entity850 formation and should be followed to monitor for their formation. Other complications are infrequent and minor.

title: Postoperative Course and Complications after Pull-through Vaginoplasty for Distal XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Children', 'patient', 'PARTICIPANTS']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['Postoperative complications']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stricture', 'vaginal stricture', 'vaginal stenosis']

entities_list: @entity365 :: ('MESH:D014627', 'Disease') :: ['vaginitis']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['postoperative urinary tract infection']

answer: @entity365 :: (MESH:D014627,Disease) :: ['Vaginal Atresia']


abstract: BACKGROUND: This single-center study assessed left subclavian artery (LSA) revascularization management and morbidity and mortality of LSA coverage outcomes during elective thoracic endovascular aortic repair (TEVAR) for distal arch @entity439 . METHODS: Between July 2006 and June 2014, 178 @entity1 underwent TEVAR (zone 2 + 3) for distal arch @entity439 . TEVAR with LSA coverage (zone 2) was performed in 121 @entity1 (68.0 %). Multivariate analysis was performed to determine factors associated with perioperative @entity385 ( @entity385 ) and @entity86 (EL). RESULTS: Technical success was achieved in 96.7 %. LSA coil embolization was performed in 72.7 %. Subclavian artery crossover bypass was required in 9.1 %. Perioperative complications were @entity385 (6.6 %) and @entity451 (1.7 %). The 30-day mortality rate was 2.5 % (n = 3). There were significant differences by @entity385 univariate analysis in coverage range (>= 300 mm) (P = 0.003) and shaggy aorta (P = 0.044). Primary EL occurred in 14.0 % (n = 17). We found statistically significant difference of primary EL in @entity1030 (P = 0.016), preoperative @entity439 diameter (P = 0.041), and proximal stent graft diameter (P = 0.029). Left upper extremity symptoms developed in 5.8 % (n = 7); @entity9085 occurred in 4.1 % (n = 5). Freedom from secondary intervention rates after 1, 3, and 5 years were 96.1, 78.3, and 63.4 %, respectively. CONCLUSIONS: Our mid- to long-term results of TEVAR with LSA coverage were generally acceptable. Routine revascularization was not necessary in majority of zone 2 TEVAR. @entity385 occurred in approximately 6 % of the cases, secondary interventions were performed more often for ELs.

title: Clinical Outcomes of Left Subclavian Artery Coverage on Morbidity and Mortality During Thoracic Endovascular Aortic Repair for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity9085 :: ('MESH:D014715', 'Disease') :: ['vertebrobasilar insufficiency']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysm']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative endoleak']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease']

entities_list: @entity451 :: ('MESH:C536857', 'Disease') :: ['paraplegia']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['CI', 'cerebral infarction']

answer: @entity439 :: (MESH:D000783,Disease) :: ['Distal Arch Aneurysms']


abstract: OBJECTIVE: Postictal elevation of high-sensitive troponin I (TNI), a highly specific biomarker for @entity741 , has been reported. We aimed at evaluating its association of high-sensitive troponin I (TNI) with @entity410 type and focus, as well as vascular risk factors. METHODS: TNI was measured in 247 @entity1 admitted to our clinic via the emergency room with an acute @entity302 . TNI control measurements were performed in 61.5% of cases. All @entity1 underwent electroencephalography and cerebral imaging. @entity410 focus - when possible - was determined using results from these examinations as well as clinical data. RESULTS: Of 247 @entity1 , 133 (53.8%) were @entity1 , the mean age was 59    18 years. 70 (28.3%) @entity1 had focal and 177 (71.7%) generalized @entity410 . @entity159 was present in 38 cases (15.4%). Mean TNI was 0.05    0.17. TNI was elevated in 27 @entity1 (10.9%). Higher age, @entity159 and temporal @entity410 focus were significantly associated with TNI elevation in multivariate analysis. In 21 (13.8%) of the @entity1 with TNI control measurement, TNI was continuously elevated. Higher age and temporal @entity410 focus were significantly associated with continuously high TNI. @entity301 and vascular risk factors were significantly associated with high TNI only in univariate analysis. No @entity1 had a symptomatic @entity741 . DISCUSSION: Postictal TNI elevation is relatively common in older @entity1 with @entity159 or temporal @entity410 focus. These data support the concept of relevant and possibly dangerous ictal effects on cardiac function especially in @entity410 . Although the risk of manifest postictal @entity583 seems to be very low, selected @entity1 could profit from closer monitoring.

title: Temporal XXXX focus and @entity159 are associated with high-sensitive troponin I elevation after @entity302 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'temporal lobe seizures', 'Seizure']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['Coronary heart disease']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic seizure']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['myocardial ischemia']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity159 :: ('MESH:D013226', 'Disease') :: ['status epilepticus', 'Status epilepticus']

answer: @entity410 :: (MESH:D012640,Disease) :: ['seizure']


abstract: OBJECTIVE: Postictal elevation of high-sensitive troponin I (TNI), a highly specific biomarker for @entity741 , has been reported. We aimed at evaluating its association of high-sensitive troponin I (TNI) with @entity410 type and focus, as well as vascular risk factors. METHODS: TNI was measured in 247 @entity1 admitted to our clinic via the emergency room with an acute @entity302 . TNI control measurements were performed in 61.5% of cases. All @entity1 underwent electroencephalography and cerebral imaging. @entity410 focus - when possible - was determined using results from these examinations as well as clinical data. RESULTS: Of 247 @entity1 , 133 (53.8%) were @entity1 , the mean age was 59    18 years. 70 (28.3%) @entity1 had focal and 177 (71.7%) generalized @entity410 . @entity159 was present in 38 cases (15.4%). Mean TNI was 0.05    0.17. TNI was elevated in 27 @entity1 (10.9%). Higher age, @entity159 and temporal @entity410 focus were significantly associated with TNI elevation in multivariate analysis. In 21 (13.8%) of the @entity1 with TNI control measurement, TNI was continuously elevated. Higher age and temporal @entity410 focus were significantly associated with continuously high TNI. @entity301 and vascular risk factors were significantly associated with high TNI only in univariate analysis. No @entity1 had a symptomatic @entity741 . DISCUSSION: Postictal TNI elevation is relatively common in older @entity1 with @entity159 or temporal @entity410 focus. These data support the concept of relevant and possibly dangerous ictal effects on cardiac function especially in @entity410 . Although the risk of manifest postictal @entity583 seems to be very low, selected @entity1 could profit from closer monitoring.

title: Temporal @entity410 focus and XXXX are associated with high-sensitive troponin I elevation after @entity302 .

answer: @entity159 :: (MESH:D013226,Disease) :: ['status epilepticus']


abstract: OBJECTIVE: Postictal elevation of high-sensitive troponin I (TNI), a highly specific biomarker for @entity741 , has been reported. We aimed at evaluating its association of high-sensitive troponin I (TNI) with @entity410 type and focus, as well as vascular risk factors. METHODS: TNI was measured in 247 @entity1 admitted to our clinic via the emergency room with an acute @entity302 . TNI control measurements were performed in 61.5% of cases. All @entity1 underwent electroencephalography and cerebral imaging. @entity410 focus - when possible - was determined using results from these examinations as well as clinical data. RESULTS: Of 247 @entity1 , 133 (53.8%) were @entity1 , the mean age was 59    18 years. 70 (28.3%) @entity1 had focal and 177 (71.7%) generalized @entity410 . @entity159 was present in 38 cases (15.4%). Mean TNI was 0.05    0.17. TNI was elevated in 27 @entity1 (10.9%). Higher age, @entity159 and temporal @entity410 focus were significantly associated with TNI elevation in multivariate analysis. In 21 (13.8%) of the @entity1 with TNI control measurement, TNI was continuously elevated. Higher age and temporal @entity410 focus were significantly associated with continuously high TNI. @entity301 and vascular risk factors were significantly associated with high TNI only in univariate analysis. No @entity1 had a symptomatic @entity741 . DISCUSSION: Postictal TNI elevation is relatively common in older @entity1 with @entity159 or temporal @entity410 focus. These data support the concept of relevant and possibly dangerous ictal effects on cardiac function especially in @entity410 . Although the risk of manifest postictal @entity583 seems to be very low, selected @entity1 could profit from closer monitoring.

title: Temporal @entity410 focus and @entity159 are associated with high-sensitive troponin I elevation after XXXX .

answer: @entity302 :: (MESH:D004827,Disease) :: ['epileptic seizures']


abstract: Three @entity1 aged 52, 22 and 29 years, without known previous @entity299 , sustained acute @entity583 due to blunt @entity764 . A 52-year-old @entity1 without a history of @entity299 sustained an acute non-transmural lateral @entity583 following blunt @entity764 during a sledging party. No coronary arteriography was performed. The clinical course during follow-up of 3 1/2 years was uncomplicated. A 22-year-old, previously asymptomatic @entity1 developed acute transmural @entity1188 after a motor-cycle accident. Seven days later he died suddenly after an uncomplicated initial course. The autopsy demonstrated a complete @entity397 of the proximal left anterior descending artery with periarterial @entity548 , compression of this artery by the @entity548 and luminal @entity715 distal to the @entity397 . No sign of preexisting @entity453 was found. A 29-year-old @entity1 admitted to the hospital after blunt @entity764 during a football game developed an acute transmural inferior @entity1188 with an uncomplicated clinical course. Seven months later coronary arteriography demonstrated a 40% obstructive lesion of the right coronary artery, compatible with @entity715 and subsequent recanalization.

title: [Traumatic XXXX . Report of 3 cases].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity764 :: ('MESH:D013898', 'Disease') :: ['chest trauma']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['anteroseptal infarction', 'infarction']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['atherosclerotic coronary disease']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarct']


abstract: OBJECTIVE: To study the specific features of @entity242 ( @entity242 ), by providing clinicopathologic and immunohistochemical evaluations of @entity5 and the biological behavior of these @entity5 and analyzing their recurrent forms. MATERIAL AND METHODS: Ten cases of @entity242 were examined with emphasis on its clinicopathological and immunohistochemical features. RESULTS: In 9 cases, the @entity5 involved the acral part of the extremities; in one case, it was located in the superficial tissues of the thigh. All @entity5 had a classical histological pattern of @entity242 . Four cases developed local recurrences most likely due to the inadequate volume of surgical intervention. Three @entity5 held its original histological form, but one showed marked histologic progression. Immunohistochemically, all the @entity5 expressed @entity2277 . Some cases exhibited a positive reaction with @entity469 , @entity21939 , and podoplanin. CONCLUSION: Despite altered morphological patterns, the immunoprofile of recurrent @entity242 was retained. A tendency for recurrence requires that the resection margins should be meticulously investigated to exclude @entity41 .

title: [Myxoinflammatory XXXX : clinicopathologic and immunohistochemical analysis].

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['myxoinflammatory fibroblastic sarcoma', 'MIFS']

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplasms', 'tumors']

answer: @entity242 :: (MESH:D012509,Disease) :: ['fibroblastic sarcoma']


abstract: BACKGROUND: @entity2956 ( @entity2956 ) have a high prevalence and in many @entity1 @entity158 and @entity409 persist despite a range of treatments. Non-invasive brain neuromodulatory methods, namely transcranial direct current stimulation (tDCS), can provide relatively long-lasting @entity158 relief in @entity1118 @entity1 . OBJECTIVE: To define the neuromodulatory effect of five daily 2x2 motor cortex high-definition tDCS (HD-tDCS) sessions on clinical @entity158 and motor measures in chronic @entity2956 @entity1 . It is predicted that M1 HD-tDCS will selectively modulate clinical measures, by showing greater analgesic after-effects compared to placebo, and active treatment will increase @entity158 more than placebo. METHODS: Twenty-four females with chronic myofascial @entity2531 underwent five daily, 20-min sessions of active or sham 2 milliamps (mA) HD-tDCS. Measurable outcomes included @entity158 opening, visual analog scale (VAS), sectional sensory-discriminative @entity158 measures tracked by a mobile application, short form of the McGill Pain Questionnaire, and the Positive and Negative Affect Schedule. Follow-up occurred at one-week and four-weeks post-treatment. RESULTS: There were significant improvements for clinical @entity158 and motor measurements in the active HD-tDCS group compared to the placebo group for: responders with @entity158 relief above 50% in the VAS at four-week follow-up (P  =  0.04); @entity158 opening at one-week follow-up (P  <  0.01); and sectional @entity158 area, intensity and their sum measures contralateral to putative M1 stimulation during the treatment week (P  <  0.01). No changes in emotional values were shown between groups. CONCLUSION: Putative M1 stimulation by HD-tDCS selectively improved meaningful clinical sensory-discriminative @entity158 and motor measures during stimulation, and up to four-weeks post-treatment in chronic myofascial @entity2531 @entity1 .

title: High-Definition and Non-invasive Brain Modulation of Pain and  Motor Dysfunction in Chronic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2956 :: ('MESH:D013705', 'Disease') :: ['TMD', 'Temporomandibular disorders']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['masticatory dysfunction']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain free jaw movement', 'pain', 'pain-free mouth']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

answer: @entity2956 :: (MESH:D013705,Disease) :: ['TMD']


abstract: An isotope washout technique that requires inexpensive equipment and is well tolerated by @entity1 has been developed to measure skin perfusion pressure (SPP) and skin vascular resistance (SVR). The SPP is a measure of the severity of @entity1095 and the SVR is an indicator of @entity455 associated with @entity6 and @entity101 . This test has been applied to 87 @entity1 who had @entity2806 of the lower limb. Fourty-four @entity1 had lesions that healed with local treatment while the other 43 required major surgery. The presence of @entity6 , @entity101 , and old age reduced the likelihood of healing. Similarly if the SPP less than 40 mm Hg, only 18% of @entity1 ' lesions healed. If the SPP lay between 40 and 50 mm Hg and the SVR less than 1000 U, 67% of lesions healed. However, if the SPP was between 40 and 50 mm Hg and the SVR greater than 1000 U, no lesions healed. If the SPP greater than 50 mm Hg and SVR less than 1000 U, 83% of lesions healed, where as if the SVR greater than 1000 U, healing occurred in only 23% of lesions. This test can be used to predict the likelihood of healing of @entity2806 of the lower leg, thus rationalizing their management. The importance of @entity455 is also demonstrated.

title: Skin vascular resistance and skin perfusion pressure as predictors of healing of @entity2806 of the lower limb: influences of @entity6 , XXXX , and age.

entities_list: @entity1095 :: ('MESH:D016491', 'Disease') :: ['peripheral vascular disease']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['microangiopathy']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'diabetes mellitus']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['ischemic lesions']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: An isotope washout technique that requires inexpensive equipment and is well tolerated by @entity1 has been developed to measure skin perfusion pressure (SPP) and skin vascular resistance (SVR). The SPP is a measure of the severity of @entity1095 and the SVR is an indicator of @entity455 associated with @entity6 and @entity101 . This test has been applied to 87 @entity1 who had @entity2806 of the lower limb. Fourty-four @entity1 had lesions that healed with local treatment while the other 43 required major surgery. The presence of @entity6 , @entity101 , and old age reduced the likelihood of healing. Similarly if the SPP less than 40 mm Hg, only 18% of @entity1 ' lesions healed. If the SPP lay between 40 and 50 mm Hg and the SVR less than 1000 U, 67% of lesions healed. However, if the SPP was between 40 and 50 mm Hg and the SVR greater than 1000 U, no lesions healed. If the SPP greater than 50 mm Hg and SVR less than 1000 U, 83% of lesions healed, where as if the SVR greater than 1000 U, healing occurred in only 23% of lesions. This test can be used to predict the likelihood of healing of @entity2806 of the lower leg, thus rationalizing their management. The importance of @entity455 is also demonstrated.

title: Skin vascular resistance and skin perfusion pressure as predictors of healing of XXXX of the lower limb: influences of @entity6 , @entity101 , and age.

answer: @entity2806 :: (MESH:D002545,Disease) :: ['ischemic lesion']


abstract: An isotope washout technique that requires inexpensive equipment and is well tolerated by @entity1 has been developed to measure skin perfusion pressure (SPP) and skin vascular resistance (SVR). The SPP is a measure of the severity of @entity1095 and the SVR is an indicator of @entity455 associated with @entity6 and @entity101 . This test has been applied to 87 @entity1 who had @entity2806 of the lower limb. Fourty-four @entity1 had lesions that healed with local treatment while the other 43 required major surgery. The presence of @entity6 , @entity101 , and old age reduced the likelihood of healing. Similarly if the SPP less than 40 mm Hg, only 18% of @entity1 ' lesions healed. If the SPP lay between 40 and 50 mm Hg and the SVR less than 1000 U, 67% of lesions healed. However, if the SPP was between 40 and 50 mm Hg and the SVR greater than 1000 U, no lesions healed. If the SPP greater than 50 mm Hg and SVR less than 1000 U, 83% of lesions healed, where as if the SVR greater than 1000 U, healing occurred in only 23% of lesions. This test can be used to predict the likelihood of healing of @entity2806 of the lower leg, thus rationalizing their management. The importance of @entity455 is also demonstrated.

title: Skin vascular resistance and skin perfusion pressure as predictors of healing of @entity2806 of the lower limb: influences of XXXX , @entity101 , and age.

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes mellitus']


abstract: OBJECTIVES: First, this study compares the ability of an integrated model of activity and activity limitations, the International Classification of Functioning, Disability and Health (ICF), and the Theory of Planned Behaviour (TPB) to predict walking within individuals with @entity571 . Second, the effectiveness of a walking intervention in these individuals is determined. DESIGN: A series of n-of-1 studies with an AB intervention design was used. METHODS: Diary methods were used to study four community-dwelling individuals with @entity6250 . Data on @entity73 ( @entity158 , @entity158 on movement, and joint @entity2693 ), cognitions (intention, self-efficacy, and perceived controllability), and walking (step count) were collected twice daily for 12  weeks. At 6  weeks, an individually tailored, data-driven walking intervention using action planning or a control cognition manipulation was delivered. Simulation modelling analysis examined cross-correlations and differences in baseline and intervention phase means. Post-hoc mediation analyses examined theoretical relationships and multiple regression analyses compared theoretical models. RESULTS: Cognitions, intention in particular, were better and more consistent within individual predictors of walking than impairment. The walking intervention did not increase walking in any of the three @entity1 receiving it. The integrated model and the TPB, which recognize a predictive role for cognitions, were significant predictors of walking variance in all @entity1 , whilst the biomedical ICF model was only predictive for one @entity1 . CONCLUSION: Despite the lack of evidence for an individually tailored walking intervention, predictive data suggest that interventions for @entity1 with @entity571 that address cognitions are likely to be more effective than those that @entity73 only. Further within-individual investigation, including testing mediational relationships, is warranted. Statement of contribution What is already known on this subject? N-of-1 methods have been used to study within-individual predictors of walking in healthy and @entity1118 populations An integrated biomedical and behavioural model of activity and activity limitations recognizes the roles of impairment and psychology (cognitions) Interventions modifying cognitions can increase physical activity in @entity1 with mobility limitations What does this study add? N-of-1 methods are suitable to study within-individual predictors of walking and interventions in @entity571 An integrated and a psychological model are better predictors of walking in @entity571 than a biomedical model There was no support for an individually tailored, data-driven walking intervention.

title: Using impairment and cognitions to predict walking in XXXX : A series of n-of-1 studies with an individually tailored, data-driven intervention.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'participant', 'people']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impairment symptoms', 'address impairment']

entities_list: @entity6250 :: ('MESH:D038061', 'Disease') :: ['lower-limb osteoarthritis']

entities_list: @entity2693 :: ('MESH:C566112', 'Disease') :: ['stiffness']

answer: @entity571 :: (MESH:D010003,Disease) :: ['osteoarthritis']


abstract: UNASSIGNED: Due to a lack of proper drug carriers to deliver treatments for @entity33 , many @entity5 @entity1 suffer from @entity3136 caused by chemotherapy and radiotherapy. We prepared a double-layered electrospun nanofibrous sheets composed of @entity21049 and chitosan to accelerate the healing rate of oral mucous @entity1066 . @entity1 growth hormone (hGH) and @entity21049 in a mixture of @entity9105 and @entity1068 were co-electrospun to nanofibrous sheets. The electrospun fibrous mat was subsequently layered with chitosan by a dip-coating method. @entity655 showed attenuated mass erosion while uncoated sheets were instantly melted at the physiological condition. The released hGH was trapped on the chitosan layer by the ionic interaction between positively charged chitosan and negatively charged hGH, and a large number of entrapped proteins remained on the SIS membrane due to the muco-adhesive properties of chitosan. hGH-incorporated sheets significantly increased proliferation of @entity1 dermal fibroblasts. In vivo study employing oral @entity1066 in @entity235 , the @entity1066 dressed with chitosan-layered sheets showed enhanced wound recovery and the chitosan layers on the sheet greatly assisted prolonged recovery. Therefore, chitosan-layered @entity21049 nanofibrous sheets can be potentially applied to developing muco-adhesive wound dressing materials with pH-dependent drug release by adjusting the thickness of chitosan sheath on the sheets.    2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2015.

title: Buccal adhesive nanofibers containing @entity1 growth hormone for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'Human']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['oral mucositis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis']

entities_list: @entity9105 :: ('MESH:C013959', 'Chemical') :: ['dimethylacetamide']

entities_list: @entity655 :: ('MESH:C535504', 'Disease') :: ['Chitosan-layered sheets']

answer: @entity3136 :: (MESH:D013280,Disease) :: ['oral mucositis']


abstract: UNASSIGNED: Due to a lack of proper drug carriers to deliver treatments for @entity33 , many @entity5 @entity1 suffer from @entity3136 caused by chemotherapy and radiotherapy. We prepared a double-layered electrospun nanofibrous sheets composed of @entity21049 and chitosan to accelerate the healing rate of oral mucous @entity1066 . @entity1 growth hormone (hGH) and @entity21049 in a mixture of @entity9105 and @entity1068 were co-electrospun to nanofibrous sheets. The electrospun fibrous mat was subsequently layered with chitosan by a dip-coating method. @entity655 showed attenuated mass erosion while uncoated sheets were instantly melted at the physiological condition. The released hGH was trapped on the chitosan layer by the ionic interaction between positively charged chitosan and negatively charged hGH, and a large number of entrapped proteins remained on the SIS membrane due to the muco-adhesive properties of chitosan. hGH-incorporated sheets significantly increased proliferation of @entity1 dermal fibroblasts. In vivo study employing oral @entity1066 in @entity235 , the @entity1066 dressed with chitosan-layered sheets showed enhanced wound recovery and the chitosan layers on the sheet greatly assisted prolonged recovery. Therefore, chitosan-layered @entity21049 nanofibrous sheets can be potentially applied to developing muco-adhesive wound dressing materials with pH-dependent drug release by adjusting the thickness of chitosan sheath on the sheets.    2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2015.

title: Buccal adhesive nanofibers containing XXXX growth hormone for @entity3136 .

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: In an effort to improve on the results of radical prostatectomy for clinical stages T2b and T3 @entity263 , a selected group of @entity1 received @entity342 deprivation for three to sixteen months prior to surgery. METHODS: Fifteen @entity1 with clinical T2b and 22 with small T3 @entity5 received a luteinizing hormone-releasing hormone analog (n = 34) or a bilateral orchiectomy (n = 3) three to sixteen months prior to radical retropubic prostatectomy. The prostate was evaluated with particular attention to @entity5 grade, presence of extracapsular extension, @entity5 at the inked margin, seminal vesicle invasion, and @entity5 in the lymph nodes. RESULTS: No @entity1 had clinical or chemical ( @entity1486 [PSA]) progression during @entity342 deprivation. The PSA level declined a mean 90 percent and remained above 4 ng/mL in only two @entity1 . The prostate volume decreased an estimated 30-50 percent. @entity263 at the inked margin was found in 15 (41%) and seminal vesicle involvement in 11 (30%) @entity1 . Five (14%) had @entity5 in regional lymph nodes. There was no difference in regard to positive margins or lymph node metastases between those clinically staged as T2b and those preoperatively staged as T3. Fourteen @entity1 have received adjuvant therapy (13 @entity342 deprivation, one radiation therapy). None has progressed (mean follow-up, 38.4 months). Of 23 who did not receive immediate additional therapy, six (26%) had progression, as was evident from an increase in PSA and have since been treated. Only one continued to progress. Thirty-five of the 37 @entity1 are alive. Seventeen (46%) are @entity5 free (PSA < 0.4 ng/mL) without further @entity342 deprivation. CONCLUSIONS: Only a prospective randomized trial can determine whether @entity342 deprivation prior to radical prostatectomy has a role. The results from this trial are encouraging for several reasons. The prostate is much smaller as a result of @entity342 deprivation and this may facilitate surgery. Although the great majority of these @entity1 were expected to be margin positive, 60 percent had negative margins and only 14 percent had positive lymph nodes.

title: @entity342 deprivation prior to radical prostatectomy for T2b and T3 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'Prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: OBJECTIVE: In an effort to improve on the results of radical prostatectomy for clinical stages T2b and T3 @entity263 , a selected group of @entity1 received @entity342 deprivation for three to sixteen months prior to surgery. METHODS: Fifteen @entity1 with clinical T2b and 22 with small T3 @entity5 received a luteinizing hormone-releasing hormone analog (n = 34) or a bilateral orchiectomy (n = 3) three to sixteen months prior to radical retropubic prostatectomy. The prostate was evaluated with particular attention to @entity5 grade, presence of extracapsular extension, @entity5 at the inked margin, seminal vesicle invasion, and @entity5 in the lymph nodes. RESULTS: No @entity1 had clinical or chemical ( @entity1486 [PSA]) progression during @entity342 deprivation. The PSA level declined a mean 90 percent and remained above 4 ng/mL in only two @entity1 . The prostate volume decreased an estimated 30-50 percent. @entity263 at the inked margin was found in 15 (41%) and seminal vesicle involvement in 11 (30%) @entity1 . Five (14%) had @entity5 in regional lymph nodes. There was no difference in regard to positive margins or lymph node metastases between those clinically staged as T2b and those preoperatively staged as T3. Fourteen @entity1 have received adjuvant therapy (13 @entity342 deprivation, one radiation therapy). None has progressed (mean follow-up, 38.4 months). Of 23 who did not receive immediate additional therapy, six (26%) had progression, as was evident from an increase in PSA and have since been treated. Only one continued to progress. Thirty-five of the 37 @entity1 are alive. Seventeen (46%) are @entity5 free (PSA < 0.4 ng/mL) without further @entity342 deprivation. CONCLUSIONS: Only a prospective randomized trial can determine whether @entity342 deprivation prior to radical prostatectomy has a role. The results from this trial are encouraging for several reasons. The prostate is much smaller as a result of @entity342 deprivation and this may facilitate surgery. Although the great majority of these @entity1 were expected to be margin positive, 60 percent had negative margins and only 14 percent had positive lymph nodes.

title: XXXX deprivation prior to radical prostatectomy for T2b and T3 @entity263 .

answer: @entity342 :: (CHEBI:50113,Chemical) :: ['Androgen']


abstract: Diquat @entity137 to the lung was evaluated in @entity35 . Diquat was administered intratracheally (i.t.) and its toxic potential was compared with that of @entity6453 . Diquat showed toxic effects in the lung when administered i.t. In previous research, diquat administered by the intravenous (i.v.) or oral (p.o.) route had little effect on the lung. a sufficient dose of @entity8229 administered i.t. would be potentially toxic to the lung, but diquat is much less toxic to the lung than @entity6453 , which is actively taken up by lung tissue. This suggests that diquat is not actively taken up by lung tissue when administered i.t., but may be passively taken up by the lung tissue and induce @entity358 .

title: The toxic effect of diquat on the XXXX lung after intratracheal administration.

entities_list: @entity6453 :: ('MESH:D010269', 'Chemical') :: ['paraquat']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['lung damage']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: Primary @entity9676 is a rare congenital condition associated with @entity6518 . @entity7893 and @entity2905 secondary to this condition are frequent but infectious complications are not. So far few immunological studies have been made in these @entity1 . We report here the results of such a study carried out in two adolescents. Both @entity1 presented with a dramatic decrease in serum gammaglobulins, especially IgG and IgA, and in peripheral blood lymphocytes, especially @entity404 T helper cells. From a functional standpoint, the proliferative response to certain mitogens was reduced. A decrease in in vitro production of immunoglobulins by B lymphocytes may be due to a faulty T/B cell cooperation. Histological examination of duodenal biopsy specimens revealed a decreased number of intraepithelial lymphocytes. Colonoscopy revealed @entity4383 in the terminal ileum, confirmed by endoscopic biopsy. The role of these abnormalities in the development of infectious complications and @entity706 is underscored.

title: Immunological study in primary XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma']

entities_list: @entity2905 :: ('MESH:D008231', 'Disease') :: ['lymphopenia']

entities_list: @entity6518 :: ('MESH:D011504', 'Disease') :: ['protein-losing enteropathy']

entities_list: @entity4383 :: ('MESH:D020518', 'Disease') :: ['nodular lymphoid hyperplasia']

entities_list: @entity7893 :: ('MESH:D000361', 'Disease') :: ['Hypogammaglobulinemia']

entities_list: @entity9676 :: ('MESH:D008201', 'Disease') :: ['intestinal lymphangiectasia']

answer: @entity9676 :: (MESH:D008201,Disease) :: ['intestinal lymphangiectasia']


abstract: BACKGROUND: In the literature laser treatment in @entity2994 ( @entity2994 ) is established to prevent @entity1539 . We investigated the relationship of morphological and fluorescein angiographic findings with the results of laser treatment. @entity1 AND METHODS: In 70 (56%) of 125 examined @entity1 with @entity2994 laser treatment was performed. Indications were either @entity5327 or @entity1103 with visual acuity < or = 0.5. RESULTS: The results compare visual acuity before and after laser treatment (three months and 11.5 months on average) examined by Wilcoxon-test. There was no significant improvement in visual acuity (p = 0.62). After laser treatment 3 (9%) @entity1 with @entity63 @entity2994 developed @entity1539 and 2 (6%) @entity2297 . There was no correlation between visual outcome and @entity63 type (non @entity63 type p = 0.61, @entity63 type p = 0.67), @entity1020 (cystoid macula @entity4 p = 0.87, @entity63 @entity1020 p = 0.5) and internal diseases ( @entity101 p = 0.43, @entity6 p = 0.74). CONCLUSIONS: The results of this study indicate that there is no significant visual improvement in @entity1 with @entity2994 after laser treatment. There are no morphological and angiographic findings indicating a subgroup with good visual prognosis.

title: [Results of laser coagulation of XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1539 :: ('MESH:D007499', 'Disease') :: ['iris neovascularization']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity2994 :: ('MESH:D012170', 'Disease') :: ['ischemic central retinal vein occlusion', 'central retinal vein occlusion', 'CRVO']

entities_list: @entity1103 :: ('MESH:D008269', 'Disease') :: ['macular edema']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['maculopathy']

entities_list: @entity5327 :: ('MESH:D065666', 'Disease') :: ['ischemic type of occlusion']

entities_list: @entity2297 :: ('MESH:D015355', 'Disease') :: ['neovascular glaucoma']

answer: @entity2994 :: (MESH:D012170,Disease) :: ['central retinal vein occlusion']


abstract: PURPOSE: The purpose of this phase 2 study was to determine the potential efficacy and safety of systemic alpha interferon in the treatment of subfoveal @entity1940 associated with age-related macular @entity2194 . METHOD: Subcutaneous alpha interferon was administered to 24 @entity1 (24 eyes), and they were prospectively studied. Alpha interferon was administered subcutaneously four times daily at a dose of 3 x 10(6) U/m2 (average total dose, 204 MU). The studied parameters included best-corrected visual acuity, membrane size, blood, exudates, and subretinal fluid. Toxic effects and performance status were graded according to the National @entity5 Institute @entity137 criteria and Karnofsky performance scale, respectively. RESULTS: Of the 24 treated eyes, 5 (21%) showed objective evidence of anatomic improvement, as defined by decrease in membrane size or improvement in fluorescein angiographic characteristics, but in only 3 of these 5 was the improvement maintained. The same three @entity1 achieved and maintained functional success (visual improvement). Two of the five @entity1 with initial anatomic improvement had subsequent membrane recurrence, which resulted in no visual change in one but @entity227 in the other. For the majority of @entity1 , the anatomic and visual status remained the same or became worse after treatment. All @entity1 experienced some degree of adverse reactions involving multiple organ systems. Decreased performance status affected 80% of the @entity1 . CONCLUSION: This study documents that regression of @entity1940 that occurred with alpha interferon treatment was minimal. Toxic effects interfering with @entity1 ' performance status are associated with alpha interferon treatment. Although a randomized trial of interferon versus no therapy may be warranted, fundamental issues (i.e., the biologic properties of interferon versus other more potent agents against @entity1940 , medication dosages, and routes of administration), need to be addressed before embarking on such a trial.

title: The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and XXXX study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['degeneration or ocular histoplasmosis']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1940 :: ('MESH:D020256', 'Disease') :: ['choroidal neovascularization']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

answer: @entity137 :: (MESH:D064420,Disease) :: ['toxicity']


abstract: We have found a monoclonal antibody, called BV7, that rapidly stimulated by 6-10-folds HT-29 @entity694 cell adhesion to resting @entity1 umbilical vein endothelial cells. This effect was directed to @entity5 cells and not to endothelial cells and was cell-specific. BV7 was also active on the HCCP-2998 but did not change adhesion to endothelial cells of other @entity5 cells (MG63 @entity421 , @entity320 , MHCC-1410 and Lovo @entity694 ) even if, by flow cytometry, this monoclonal antibody could bind to them. Additionally, BV7 effect was substratum-specific, since it did not increase but rather blocked HT-29 adhesion to matrix proteins. Immunoprecipitation analysis and binding to specific transfectants revealed that BV7 recognizes beta 1-subunit of integrin receptors and antibody blocking experiments showed that alpha 2 beta 1 antibodies were able to counteract BV7 effect on HT-29 adhesion to endothelial cells. In contrast, antibodies directed to other integrins or endothelial adhesive receptors (E- and @entity8729 , @entity4725 , @entity2071 , @entity10985 ) were ineffective. Induction of HT-29 adhesion to endothelial cells by BV7 was Fc- and protein synthesis-independent but required metabolically active cells. The presence of physiological concentrations of divalent cations and of cytoskeletal integrity was not needed. Comparative studies with eight different prototypic beta 1 antibodies showed that five of them induced HT-29 adhesion to endothelial cells in a way unrelated to their ability to interfere with HT-29 adhesion to matrix proteins. Cross-blocking binding assays demonstrated that all the five antibodies recognized a topographically related epitope. Taken together these results provide evidence that beta 1 antibodies may trigger a novel pathway of HT-29 @entity694 adhesion to endothelial cells with different features in respect to other described mechanisms of @entity5 cell interaction with the endothelium.

title: A novel mechanism of XXXX cell adhesion to the endothelium triggered by beta 1 integrin chain.

entities_list: @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcoma']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon carcinoma']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colon carcinoma']


abstract: Various snake venom peptides have been extensively evaluated for use as antithrombotic agents. Recently, it was determined that the snake venom peptide sarafotoxin S6b (S6b) is structurally similar to the potent vasoactive hormone @entity11976 ( @entity11976 ), which has been shown to inhibit agonist-induced @entity1423 . The potential in vivo antithrombotic activity of S6b was compared with that of @entity11976 , a much more potent pressor agent than S6b, by evaluating the effects of S6b and @entity11976 (0.5 microgram/kg i.v.) on repetitive @entity1423 formation (RPTF) in the stenosed @entity235 circumflex coronary artery. In this model platelets adhere to the damaged vessel wall near a mechanically produced @entity850 . As platelets aggregate at this site, blood flow gradually declines until the vessel is completely occluded. The @entity715 is then physically dislodged, thus restoring flow. The blood flow pattern resulting from RPTF is referred to as cyclic flow reductions (CFRs). Injection of S6b or @entity11976 blocked RPTF, as indicated by inhibition of CFRs. On a rating system of 0 (no effect) to 3 (complete inhibition), S6b and @entity11976 produced CFR ratings of 1.8 +/- 0.5 (n = 6) and 2.0 +/- 0.4 (n = 6), respectively. This effect was not blocked by pretreatment with @entity117 at 5 mg/kg i.v., a dose that abolishes @entity1426 -induced ex vivo @entity1423 (CFR scores for S6b and @entity11976 were 2.6 +/- 0.2, n = 5 and 2.0 +/- 0.3, n = 5, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

title: The snake venom peptide sarafotoxin S6b inhibits repetitive XXXX formation in the stenosed @entity235 coronary artery.

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet thrombus', 'platelet aggregation']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity1426 :: ('MESH:D016718', 'Chemical') :: ['arachidonic acid']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity1423 :: (MESH:D001791,Disease) :: ['platelet thrombus']


abstract: Various snake venom peptides have been extensively evaluated for use as antithrombotic agents. Recently, it was determined that the snake venom peptide sarafotoxin S6b (S6b) is structurally similar to the potent vasoactive hormone @entity11976 ( @entity11976 ), which has been shown to inhibit agonist-induced @entity1423 . The potential in vivo antithrombotic activity of S6b was compared with that of @entity11976 , a much more potent pressor agent than S6b, by evaluating the effects of S6b and @entity11976 (0.5 microgram/kg i.v.) on repetitive @entity1423 formation (RPTF) in the stenosed @entity235 circumflex coronary artery. In this model platelets adhere to the damaged vessel wall near a mechanically produced @entity850 . As platelets aggregate at this site, blood flow gradually declines until the vessel is completely occluded. The @entity715 is then physically dislodged, thus restoring flow. The blood flow pattern resulting from RPTF is referred to as cyclic flow reductions (CFRs). Injection of S6b or @entity11976 blocked RPTF, as indicated by inhibition of CFRs. On a rating system of 0 (no effect) to 3 (complete inhibition), S6b and @entity11976 produced CFR ratings of 1.8 +/- 0.5 (n = 6) and 2.0 +/- 0.4 (n = 6), respectively. This effect was not blocked by pretreatment with @entity117 at 5 mg/kg i.v., a dose that abolishes @entity1426 -induced ex vivo @entity1423 (CFR scores for S6b and @entity11976 were 2.6 +/- 0.2, n = 5 and 2.0 +/- 0.3, n = 5, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

title: The snake venom peptide sarafotoxin S6b inhibits repetitive @entity1423 formation in the stenosed XXXX coronary artery.

answer: @entity235 :: (9615,Species) :: ['canine']


abstract: Fourteen @entity1 with normal, global, left ventricular function scheduled for elective myocardial revascularization were studied at rest and during atrial pacing before and during @entity5161 anesthesia (0.5% end-tidal) plus 50% @entity3810 . Rapid atrial pacing was performed in a stepwise fashion until the onset of @entity951 in the awake @entity1 . The same step increase in pacing rate was applied in the anesthetized @entity1 . Compared with prepacing baseline values, @entity5161 significantly decreased systemic blood pressure, coronary perfusion pressure, the rate-pressure product, and cardiac index. No @entity1 had ST-segment @entity308 while awake or during @entity5161 anesthesia before pacing was started. Prepacing left and right ventricular filling pressures and wave forms were normal, both while awake and during @entity5161 anesthesia. The mean pacing rate at which first signs of @entity741 appeared (V5 ST-segment @entity308 greater than or equal to 0.1 mV, increase in pulmonary capillary wedge pressure (PCWP) to greater than or equal to 15 mmHg, and prominent PCWP v-waves greater than or equal to 20 mmHg) was significantly higher during @entity5161 anesthesia than in the awake @entity1 (128 +/- 4 vs. 115 +/- 5 beats/min). With the exception of one @entity1 , the individual pacing rates inducing first signs of @entity63 in the awake @entity1 were below the anginal threshold. None of the @entity1 had a reduced @entity63 threshold during anesthesia. Eleven anesthetized @entity1 tolerated a higher pacing rate until initial signs of @entity63 appeared. In four of these @entity1 , the pacing rate required to induce first signs of @entity63 was above the heart rate at which @entity662 had been induced while they were awake. At a peak atrial pacing rate of 129 +/- 5 beats/min, which had induced @entity951 in the awake @entity1 , the increase in PCWP was significantly smaller during pacing with @entity5161 than during control pacing. Prominent PCWP v-waves (greater than or equal to 20 mmHg) appeared in 12 of the 14 @entity1 during initial pacing to angina and in eight @entity1 paced during @entity5161 anesthesia. In six of these eight @entity1 , the abnormal v-waves were less prominent than those observed during control pacing. Ischemic ST-segment changes developed in 13 of 14 @entity1 during initial pacing and in nine @entity1 during pacing with @entity5161 . Mean V5 ST-segment @entity308 during the two pacing periods was significantly different, averaging 0.19 and 0.11 mV, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

title: XXXX improves the tolerance to pacing-induced @entity741 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris']

entities_list: @entity3810 :: ('MESH:D009609', 'Chemical') :: ['nitrous oxide']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['myocardial ischemia']

entities_list: @entity5161 :: ('MESH:D007530', 'Chemical') :: ['isoflurane']

answer: @entity5161 :: (MESH:D007530,Chemical) :: ['Isoflurane']


abstract: Fourteen @entity1 with normal, global, left ventricular function scheduled for elective myocardial revascularization were studied at rest and during atrial pacing before and during @entity5161 anesthesia (0.5% end-tidal) plus 50% @entity3810 . Rapid atrial pacing was performed in a stepwise fashion until the onset of @entity951 in the awake @entity1 . The same step increase in pacing rate was applied in the anesthetized @entity1 . Compared with prepacing baseline values, @entity5161 significantly decreased systemic blood pressure, coronary perfusion pressure, the rate-pressure product, and cardiac index. No @entity1 had ST-segment @entity308 while awake or during @entity5161 anesthesia before pacing was started. Prepacing left and right ventricular filling pressures and wave forms were normal, both while awake and during @entity5161 anesthesia. The mean pacing rate at which first signs of @entity741 appeared (V5 ST-segment @entity308 greater than or equal to 0.1 mV, increase in pulmonary capillary wedge pressure (PCWP) to greater than or equal to 15 mmHg, and prominent PCWP v-waves greater than or equal to 20 mmHg) was significantly higher during @entity5161 anesthesia than in the awake @entity1 (128 +/- 4 vs. 115 +/- 5 beats/min). With the exception of one @entity1 , the individual pacing rates inducing first signs of @entity63 in the awake @entity1 were below the anginal threshold. None of the @entity1 had a reduced @entity63 threshold during anesthesia. Eleven anesthetized @entity1 tolerated a higher pacing rate until initial signs of @entity63 appeared. In four of these @entity1 , the pacing rate required to induce first signs of @entity63 was above the heart rate at which @entity662 had been induced while they were awake. At a peak atrial pacing rate of 129 +/- 5 beats/min, which had induced @entity951 in the awake @entity1 , the increase in PCWP was significantly smaller during pacing with @entity5161 than during control pacing. Prominent PCWP v-waves (greater than or equal to 20 mmHg) appeared in 12 of the 14 @entity1 during initial pacing to angina and in eight @entity1 paced during @entity5161 anesthesia. In six of these eight @entity1 , the abnormal v-waves were less prominent than those observed during control pacing. Ischemic ST-segment changes developed in 13 of 14 @entity1 during initial pacing and in nine @entity1 during pacing with @entity5161 . Mean V5 ST-segment @entity308 during the two pacing periods was significantly different, averaging 0.19 and 0.11 mV, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

title: @entity5161 improves the tolerance to pacing-induced XXXX .

answer: @entity741 :: (MESH:D017202,Disease) :: ['myocardial ischemia']


abstract: @entity3569 ovary cells were maintained in culture medium supplemented with delipidated serum to make them dependent on nonlipid components for lipid synthesis. Growth in lipid-free medium resulted in an increased flux through the @entity13667 - @entity1877 pathway for @entity2434 synthesis. The increased flux appeared to be mediated by the @entity93 : @entity2945 cytidylyltransferase because cellular @entity2945 levels decreased in cells grown in lipid-free medium, and both cell-free cytidylyltransferase activity and membrane-associated cytidylyltransferase activity increased in cells grown in lipid-free medium. @entity3569 ovary cells maintained in culture medium supplemented with complete serum can grow at nearly normal rates in the presence of phospholipase C for many generations, even though the treatment enhances turnover of cellular @entity2434 (R. Sleight and C. Kent (1983) J. Biol. Chem. 258, 824-830). The phospholipase C treatment, however, was toxic to cells maintained in medium supplemented with delipidated serum. @entity6579 protected cells from phospholipase @entity137 , but did not support growth. The rate of utilization of @entity6579 for @entity2434 synthesis was about 8% of the turnover rate for @entity2434 , and was not increased by phospholipase C treatment. Reconstitution of the medium with fractionated serum lipids showed that the cells required specific neutral lipids, namely, @entity1718 plus @entity165 , in order to grow in the presence of phospholipase C. Either oleate or @entity165 (up to 80 microM) alone did not allow growth in phospholipase C, but a combination of these two lipids supported growth effectively.

title: XXXX ovary cells depend on exogenous lipids to survive phospholipase C treatment.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity6579 :: ('MESH:D008244', 'Chemical') :: ['Lysophosphatidylcholine', 'lysophosphatidylcholine']

entities_list: @entity2434 :: ('MESH:D010713', 'Chemical') :: ['phosphatidylcholine']

entities_list: @entity2945 :: ('MESH:D010767', 'Chemical') :: ['phosphocholine']

entities_list: @entity3569 :: ('10029', 'Species') :: ['Chinese hamster']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity3569 :: (10029,Species) :: ['Chinese hamster']


abstract: Eight @entity1 received allogeneic bone marrow transplantation (BMT) as therapy for @entity1860 ( @entity1860 ) using marrow from unrelated donors. In all cases donors and recipients were HLA DR identical and had low MLC reactivity. In three cases recipients received marrow that was identical at the @entity1529 ,B loci. In five cases HLA identity differed for one @entity1529 locus antigen. The unrelated donor search interval ranged from 2 to 28 months (median, 3 months). All recipients were prepared with a combination of @entity786 , 60 mg/kg/d administered intravenously (IV) (days -6,-5) and with total body irradiation administered in 165 cGy fractions twice daily for four days (days -4, -3, -2, -1). Engraftment occurred in all cases (range, 18 to 48 days; median, 35 days), and return to a complete Philadelphia chromosome (Ph') negative state was documented in six of eight cases. Moderate or severe acute @entity2132 ( @entity2132 ) occurred in seven of eight cases, and extensive chronic @entity2132 in four of six evaluable recipients. A B cell @entity1071 developed in one @entity1 . Four recipients have died within 2 to 4 months of transplant. Four of eight @entity1 survive at 11+ to 24+ months following transplantation (median, 15+ months) with normal peripheral blood counts and without evidence of @entity1778 . Current Karnofsky activity assessments are 90% or 100% in all survivors. Curative therapy of @entity1860 has been available only to the minority of @entity1 eligible for sibling donor BMT. Unrelated donor BMT can be effective in the treatment of @entity1860 and may be particularly useful in this disorder since the prolonged stable phase of disease offers an opportunity to locate suitable donors.

title: Unrelated donor bone marrow transplantation therapy for XXXX .

entities_list: @entity1071 :: ('MESH:D008232', 'Disease') :: ['lymphoproliferative disorder']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft v host disease']

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myelogenous leukemia']

answer: @entity1860 :: (MESH:D015464,Disease) :: ['chronic myelogenous leukemia']


abstract: BACKGROUND AND PURPOSE: The PIWI-interacting RNA (piRNA) is the most predominant RNA species in eukaryotes. The piRNA are a class of noncoding RNAs that bind and degrade the RNA formed by the transposons to control the transposon-induced gene mutations. The role of piRNA after focal @entity63 is not yet evaluated. METHODS: We profiled 39 727 piRNAs in the cerebral cortex of adult @entity35 subjected to transient focal @entity63 using microarrays. The RT targets of @entity64 were identified with bioinformatics. To understand how piRNAs are controlled, we analyzed the transcription factor binding sites in the putative promoters of 10 representative @entity64 . RESULTS: In the ipsilateral cortex of @entity63 @entity35 , 105 piRNAs showed altered expression (54 up- and 51 downregulated; >2.5-fold) compared with shams. Twenty-five of those showed a >5-fold change. A bioinformatics search showed that the transposon targets of the highly @entity64 are distributed among the 20 autosomal chromosomes and there is a redundancy in the targets between the piRNAs. Furthermore, the transposon targets were observed to be highly repetitious for each piRNA across the chromosome length. Of the 159 transcription factors observed to have binding sites in the piRNA gene promoters, 59% belonged to 20 major families indicating that transcription factors control @entity64 in a redundant manner. CONCLUSIONS: The present study is the first to show that many piRNAs are expressed in adult rodent brain and several of them respond to focal @entity63 .

title: Altered expression of PIWI RNA in the @entity35 brain after transient focal XXXX .

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke-responsive piRNAs']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic', 'ischemia']

answer: @entity63 :: (MESH:D007511,Disease) :: ['ischemia']


abstract: BACKGROUND AND PURPOSE: The PIWI-interacting RNA (piRNA) is the most predominant RNA species in eukaryotes. The piRNA are a class of noncoding RNAs that bind and degrade the RNA formed by the transposons to control the transposon-induced gene mutations. The role of piRNA after focal @entity63 is not yet evaluated. METHODS: We profiled 39 727 piRNAs in the cerebral cortex of adult @entity35 subjected to transient focal @entity63 using microarrays. The RT targets of @entity64 were identified with bioinformatics. To understand how piRNAs are controlled, we analyzed the transcription factor binding sites in the putative promoters of 10 representative @entity64 . RESULTS: In the ipsilateral cortex of @entity63 @entity35 , 105 piRNAs showed altered expression (54 up- and 51 downregulated; >2.5-fold) compared with shams. Twenty-five of those showed a >5-fold change. A bioinformatics search showed that the transposon targets of the highly @entity64 are distributed among the 20 autosomal chromosomes and there is a redundancy in the targets between the piRNAs. Furthermore, the transposon targets were observed to be highly repetitious for each piRNA across the chromosome length. Of the 159 transcription factors observed to have binding sites in the piRNA gene promoters, 59% belonged to 20 major families indicating that transcription factors control @entity64 in a redundant manner. CONCLUSIONS: The present study is the first to show that many piRNAs are expressed in adult rodent brain and several of them respond to focal @entity63 .

title: Altered expression of PIWI RNA in the XXXX brain after transient focal @entity63 .

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: By northern blot analysis and ribonuclease protection assay, we observed the presence of a high level of @entity10864 mRNA in primary brain cultures devoid of neuronal cells and highly enriched in glial fibrillary acidic protein-positive astroglial cells prepared from newborn @entity35 cerebral hemispheres, cerebral cortex, hippocampus, and striatum. In primary astroglial cultures, the more abundant @entity10864 transcripts code for the truncated receptor without @entity669 kinase activity; probes specific for the full-length @entity10864 mRNA did not detect any signal in northern blot analysis. By the sensitive ribonuclease protection assay, we could show the presence of @entity10865 mRNA in cultured astrocytes, whereas no @entity3249 mRNA was detected. We confirmed the presence of relatively high levels of nerve growth factor and neurotrophin-3 mRNA, and very low basal level of @entity2136 mRNA. Moreover, we demonstrated that another member of the neurotrophin family, @entity10863 , is also expressed in cultured astroglial cells. In view of the fact that many functional receptors for conventional neurotransmitters or neuropeptides present on astroglial cells may act via the @entity1920 cyclase system, we studied also the effect of agents able to increase the intracellular @entity1919 concentration. A sharp increase in the @entity10864 mRNA level was observed after treatment of primary astroglial cultures with @entity5393 , @entity5987 , or the phosphodiesterase inhibitor, @entity1922 . On the contrary, @entity10865 mRNA levels were unaffected by treatment with @entity1919 -elevating agents. All the neurotrophin mRNAs examined, except neutrophin-4, were increased by @entity1922 treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Expression of neurotrophins and their receptors in primary astroglial cultures: induction by XXXX -elevating agents.

entities_list: @entity2136 :: ('24225(Tax:10116)', 'Gene') :: ['brain-derived neurotrophic factor']

entities_list: @entity5393 :: ('MESH:D003994', 'Chemical') :: ['dibutyryl cyclic AMP']

entities_list: @entity1920 :: ('CHEBI:16027', 'Chemical') :: ['adenylate']

entities_list: @entity5987 :: ('MESH:D015124', 'Chemical') :: ['8-bromo-cyclic AMP']

entities_list: @entity1922 :: ('MESH:D015056', 'Chemical') :: ['3-isobutyl-1-methylxanthine']

entities_list: @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity1919 :: (MESH:D000242,Chemical) :: ['cyclic AMP']


abstract: UNASSIGNED: @entity311 , the most widespread mosquito-borne disease, affects 350-500 million @entity1 each year. Eco-friendly control tools against @entity311 vectors are urgently needed. This research proposed a novel method of plant-mediated synthesis of @entity575 nanoparticles (AgNP) using a cheap seaweed extract of Ulva lactuca, acting as a reducing and capping agent. AgNP were characterized by UV-vis spectrophotometry, Fourier transform infrared (FTIR) spectroscopy, energy-dispersive X-ray spectroscopy (EDX), scanning electron microscopy (SEM),  and @entity11898 ( @entity11898 ). The U. lactuca extract and the green-synthesized AgNP were tested against larvae and pupae of the @entity311 vector Anopheles stephensi. In mosquitocidal assays, LC50 values of U. lactuca extract against A. stephensi larvae and pupae were 18.365  ppm (I instar), 23.948  ppm (II), 29.701  ppm (III), 37.517  ppm (IV), and 43.012  ppm (pupae). LC50 values of AgNP against A. stephensi were 2.111  ppm (I), 3.090  ppm (II), 4.629  ppm (III), 5.261  ppm (IV), and 6.860  ppm (pupae). Smoke @entity137 experiments conducted against mosquito adults showed that U. lactuca coils evoked mortality rates comparable to the @entity315 -based positive control (66, 51, and 41  %, respectively). Furthermore, the antiplasmodial activity of U. lactuca extract and U. lactuca-synthesized AgNP was evaluated against CQ-resistant (CQ-r) and CQ-sensitive (CQ-s) strains of @entity3964 . Fifty percent inhibitory concentration (IC50) values of U. lactuca were 57.26   g/ml (CQ-s) and 66.36   g/ml (CQ-r); U. lactuca-synthesized AgNP IC50 values were 76.33   g/ml (CQ-s) and 79.13   g/ml (CQ-r). Overall, our results highlighted out that U. lactuca-synthesized AgNP may be employed to develop newer and safer agents for @entity311 control.

title: Seaweed-synthesized @entity575 nanoparticles: an eco-friendly tool in the fight against XXXX and its vector Anopheles stephensi?

entities_list: @entity11898 :: ('MESH:C564523', 'Disease') :: ['XRD', 'X-ray diffraction']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity315 :: ('MESH:D026023', 'Chemical') :: ['permethrin']

entities_list: @entity3964 :: ('5833', 'Species') :: ['Plasmodium falciparum']

entities_list: @entity311 :: ('MESH:D008288', 'Disease') :: ['Malaria', 'malaria']

answer: @entity3964 :: (5833,Species) :: ['Plasmodium falciparum']


abstract: UNASSIGNED: @entity311 , the most widespread mosquito-borne disease, affects 350-500 million @entity1 each year. Eco-friendly control tools against @entity311 vectors are urgently needed. This research proposed a novel method of plant-mediated synthesis of @entity575 nanoparticles (AgNP) using a cheap seaweed extract of Ulva lactuca, acting as a reducing and capping agent. AgNP were characterized by UV-vis spectrophotometry, Fourier transform infrared (FTIR) spectroscopy, energy-dispersive X-ray spectroscopy (EDX), scanning electron microscopy (SEM),  and @entity11898 ( @entity11898 ). The U. lactuca extract and the green-synthesized AgNP were tested against larvae and pupae of the @entity311 vector Anopheles stephensi. In mosquitocidal assays, LC50 values of U. lactuca extract against A. stephensi larvae and pupae were 18.365  ppm (I instar), 23.948  ppm (II), 29.701  ppm (III), 37.517  ppm (IV), and 43.012  ppm (pupae). LC50 values of AgNP against A. stephensi were 2.111  ppm (I), 3.090  ppm (II), 4.629  ppm (III), 5.261  ppm (IV), and 6.860  ppm (pupae). Smoke @entity137 experiments conducted against mosquito adults showed that U. lactuca coils evoked mortality rates comparable to the @entity315 -based positive control (66, 51, and 41  %, respectively). Furthermore, the antiplasmodial activity of U. lactuca extract and U. lactuca-synthesized AgNP was evaluated against CQ-resistant (CQ-r) and CQ-sensitive (CQ-s) strains of @entity3964 . Fifty percent inhibitory concentration (IC50) values of U. lactuca were 57.26   g/ml (CQ-s) and 66.36   g/ml (CQ-r); U. lactuca-synthesized AgNP IC50 values were 76.33   g/ml (CQ-s) and 79.13   g/ml (CQ-r). Overall, our results highlighted out that U. lactuca-synthesized AgNP may be employed to develop newer and safer agents for @entity311 control.

title: Seaweed-synthesized XXXX nanoparticles: an eco-friendly tool in the fight against @entity3964 and its vector Anopheles stephensi?

answer: @entity575 :: (MESH:D012834,Chemical) :: ['silver']


abstract: BACKGROUND: Differences between centers in @entity1 outcome after @entity131 are of importance for multicenter studies and have seldom been studied. OBJECTIVE: To quantify the differences in centers enrolling @entity1 in randomized clinical trials (RCTs) and surveys. METHODS: We analyzed individual @entity1 data from 9578 @entity1 with moderate and severe @entity131 enrolled in 10 RCTs and 3 observational studies. We used random-effects logistic regression models to estimate the between-center differences in unfavorable outcome (dead, vegetative state, or severe disability measured with the Glasgow Outcome Scale) at 6 months adjusted for differences in @entity1 characteristics. We calculated the difference in odds of unfavorable outcome between the centers at the higher end vs those at the lower end of the outcome distribution. We analyzed the total database, Europe and the United States separately, and 4 larger RCTs. RESULTS: The 9578 @entity1 were enrolled at 265 centers, and 4629 (48%) had an unfavorable outcome. After adjustment for @entity1 characteristics, there was a 3.3-fold difference in the odds of unfavorable outcome between the centers at the lower end of the outcome distribution (2.5th percentile) vs those at the higher end of the outcome distribution (97.5th percentile; P<.001). In the 4 larger RCTs, the differences between centers were similar. However, differences were smaller between centers in the United States (2.4-fold) than between centers in Europe (3.8-fold). CONCLUSION: Outcome after @entity131 differs substantially between centers, particularly in Europe. Further research is needed to study explanations for these differences to suggest where quality of care might be improved.

title: Large between-center differences in outcome after moderate and severe XXXX in the international mission on prognosis and clinical trial design in @entity131 (IMPACT) study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['traumatic brain injury']

answer: @entity131 :: (MESH:D001930,Disease) :: ['traumatic brain injury']